- Home
- SGD vs CYCC Comparison
SGD vs CYCC Comparison
Compare SGD & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGD
- CYCC
- Stock Information
- Founded
- SGD 2021
- CYCC 1992
- Country
- SGD United States
- CYCC United States
- Employees
- SGD N/A
- CYCC N/A
- Industry
- SGD
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- SGD
- CYCC Health Care
- Exchange
- SGD Nasdaq
- CYCC Nasdaq
- Market Cap
- SGD 2.6M
- CYCC 2.2M
- IPO Year
- SGD N/A
- CYCC N/A
- Fundamental
- Price
- SGD $1.50
- CYCC $0.34
- Analyst Decision
- SGD
- CYCC Strong Buy
- Analyst Count
- SGD 0
- CYCC 1
- Target Price
- SGD N/A
- CYCC $11.00
- AVG Volume (30 Days)
- SGD 703.6K
- CYCC 6.4M
- Earning Date
- SGD 01-01-0001
- CYCC 03-18-2025
- Dividend Yield
- SGD N/A
- CYCC N/A
- EPS Growth
- SGD N/A
- CYCC N/A
- EPS
- SGD N/A
- CYCC N/A
- Revenue
- SGD $173,188.00
- CYCC $74,000.00
- Revenue This Year
- SGD N/A
- CYCC N/A
- Revenue Next Year
- SGD N/A
- CYCC $88.68
- P/E Ratio
- SGD N/A
- CYCC N/A
- Revenue Growth
- SGD N/A
- CYCC N/A
- 52 Week Low
- SGD $1.40
- CYCC $0.31
- 52 Week High
- SGD $53.80
- CYCC $4.00
- Technical
- Relative Strength Index (RSI)
- SGD 30.63
- CYCC 44.48
- Support Level
- SGD $1.40
- CYCC $0.32
- Resistance Level
- SGD $1.70
- CYCC $0.41
- Average True Range (ATR)
- SGD 0.22
- CYCC 0.03
- MACD
- SGD -0.03
- CYCC -0.00
- Stochastic Oscillator
- SGD 7.46
- CYCC 31.11
About SGD Safe and Green Development Corporation
Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe & Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partner with third-party equity investors or other developers.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.